According to a recent study, a new type of blood test should be used in primary healthcare in targeted patients whose risk of progressive steatotic, or fatty, liver disease has been found to be elevated in standard laboratory tests. The test costs just under €100, making it cost efficient compared to a liver biopsy.
"This is not just a question about a new test, but improving the care pathway. The blood test can already be taken when visiting primary healthcare. This will allow obtaining information on the disease and making a more accurate risk assessment more quickly, meaning that intensive treatment can be initiated sooner. The current model leads to unnecessary referrals to specialised care and long waiting periods. In addition, the majority of patients with the disease are not identified and are left without effective follow-up care," says Docent Sami Qadri from HUS Helsinki University Hospital and the University of Helsinki.
Many people suffer from steatotic liver disease without knowing it
As many as one in three Finns has steatotic liver disease, and the disease is becoming increasingly common. The main cause is increased abdominal obesity. Alcohol use is also a significant underlying factor, and is particularly harmful when combined with obesity. Since steatotic liver disease is asymptomatic for a long time, as many as 95% of patients do not know they have it. When left untreated, the disease may eventually scar the liver permanently, resulting in cirrhosis of the liver. For many, the first symptoms occur only when liver function begins to fail. At that stage, the only cure is a liver transplant.
A blood test can be used to assess the prognosis of liver disease and the need for therapeutic intervention. When a blood test is combined with imaging in specialised care, the stage of the disease and the need for medication are often resolved without biopsies. Biopsies are expensive and may be associated with rare but serious adverse effects.
However, the test is not a means for population screening but a risk assessment tool. It is already in use in, for example, HUS laboratories.
The study changes the Current Care Guidelines
"This project is an excellent example of how research benefits patients in the form of increasingly better diagnostics and therapies. It is also our aim to bring these new research findings to the Current Care Guidelines for steatotic liver disease, which will be updated at the end of the year," says Sami Qadri.
The results were obtained in the LITMUS project involving 53 international university and business partners, including the University of Helsinki. The project was funded by the European Innovative Medicines Initiative 2 Joint Undertaking.
In the project, the researchers compared imaging methods, regular blood tests and expensive specialised tests in the detection of advanced steatotic liver disease. Biopsies and biomarkers of roughly 1,500 individuals were assessed in a centralised manner, making the comparison exceptionally reliable.
During the project, the researchers also identified another promising patented test measuring several blood proteins, which predicted the risk of liver scarring surprisingly well. However, this test is not yet available in healthcare but requires further research and a price reduction.
Research publication: , The Lancet